MNKD MannKind Corporation
USHealthcareAs of 2026-07-08 14:47
Why MNKD matters now
MannKind Corporation (MNKD) is a US stock in Healthcare. The latest InvestLog snapshot shows $4.22 with -0.12% on the session and $1.30B in market capitalization; recent performance reads 1-month +33.11% and YTD -30.51%.
The latest financial table shown here is Q1 2026, with revenue of $90.2M, net income of $-16.6M, and EPS of $-0.05. Investors can compare that operating picture with valuation signals such as P/E 135.05 and FCF yield 1.0%.
The latest indexable market news headline is "MannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza® in Youth with Newly-Diagnosed T1D" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $8.50; recent insider activity includes Kay Sabrina filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
135.05
PEG
—
P/B
-20.52
P/S
3.37
EV/EBITDA
58.11
DCF Value
$-38.87
FCF Yield
1.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
76.0%
Operating Margin
3.7%
Net Margin
-6.6%
ROE
45.6%
ROA
-3.2%
ROIC
1.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $90.2M | $-16.6M | $-0.05 |
| Q4 2025 | $112.0M | $-15.9M | $-0.05 |
| FY 2025 | $349.0M | $5.9M | $0.02 |
| Q3 2025 | $82.1M | $8.0M | $0.03 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$8.50
Target (Median)
$8.50
Target Range
$6.00 - $11.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.11
MannKind Corporation operates as a biopharmaceutical firm, primarily focused on innovating and bringing to market respiratory-delivered treatments. Its efforts are directed towards tackling endocrine system disorders and rare lung conditions within the U.S. market. The company's key product is Afrezza, an inhaled insulin designed to improve glycemic control for adults managing diabetes. MannKind also actively markets Thyquidity, promoting it to adult and pediatric endocrinologists and other healthcare professionals for the treatment of hypothyroidism. In terms of collaborations, MannKind holds a strategic licensing and partnership agreement with United Therapeutics Corporation. Furthermore, it is collaborating with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), which is a synthetic variant of human vasoactive intestinal peptide intended to shield cells from inflammatory processes. Established in 1991, MannKind Corporation's corporate offices are located in Westlake Village, California.